Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: schizophrenia/schizoaffective disorder. Clear all
Completed Not applicable Interventional Results available

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

NCT00963924
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo, Cognitive Remediation
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging

NCT00288340
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Hallucinations
Interventions
functional magnetic resonance imaging
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 1 Interventional

Digoxin Drug-Drug Interaction With Lurasidone HCl

NCT01082289
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 6:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

NCT01384604
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 70 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 1Phase 2 Interventional

Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia

NCT01292577
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CET/PT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

NCT03408873
View directory record Official record
Conditions
Bipolar Disorder, Medication Adherence, Medication Non Adherence
Interventions
Abilify Maintena, Customized Adherence Enhancement (CAE)
Drug · Behavioral
Lead sponsor
Martha Sajatovic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 7, 2026, 6:50 AM EDT
Withdrawn Not applicable Interventional

Home-based Exercise for SMI

NCT06078293
View directory record Official record
Conditions
Serious Mental Illness
Interventions
Home-based Exercise Program
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional

Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network

NCT00930150
View directory record Official record
Conditions
Schizophrenia
Interventions
Targeted cognitive training, Computer control, Bridging groups, Health and wellness groups
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
New Haven, Connecticut • Atlanta, Georgia • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

NCT00001656
View directory record Official record
Conditions
Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
Interventions
Olanzapine, Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

NCT00206102
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine fumarate, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 7, 2026, 6:50 AM EDT
Withdrawn Not applicable Interventional

Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

NCT04068857
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
rTMS
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 7, 2026, 6:50 AM EDT
Recruiting Phase 4 Interventional

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

NCT03495024
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Interventions
Varenicline
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 7, 2026, 6:50 AM EDT
Completed No phase listed Observational

Vocal Acoustic Biomarkers in Depression

NCT00844948
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Center for Psychological Research, Madison, WI
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional

Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder

NCT00501618
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Fazaclo
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 7, 2026, 6:50 AM EDT
Recruiting Not applicable Interventional

Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder

NCT06221852
View directory record Official record
Conditions
Bipolar I Disorder, Psychosis, Schizoaffective Disorder
Interventions
Ketogenic diet, Dietary Guidelines for Americans
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCT00644969
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Aurora, Colorado • Farmington, Connecticut • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 7, 2026, 6:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ocrelizumab for Psychosis by Autoimmunity

NCT03971487
View directory record Official record
Conditions
Schizo-Affective Type of Psychosis, Schizophrenia
Interventions
Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
Behavioral · Diagnostic Test · Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Results available

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907
View directory record Official record
Conditions
Schizophrenia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Palo Alto, California • Boca Raton, Florida • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Galantamine for Cognition in People With Schizophrenia

NCT00320736
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2009 · Synced Oct 7, 2026, 6:50 AM EDT
Completed Phase 2 Interventional

Cognitive Training to Improve Work Outcomes in Severe Mental Illness

NCT00895258
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression
Interventions
Individual placement and support plus cognitive training (IPS-CT), Individual placement and support plus enhanced support (IPS-ES)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 7, 2026, 6:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Striatal Connectivity and Clinical Outcome in Psychosis

NCT02822092
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Risperidone or Aripiprazole (patients only)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 7, 2026, 6:50 AM EDT